Activity of OSE-2101 in HLA-A2+non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
dc.conference.date | SEP 19-OCT 18, 2020 | |
dc.conference.title | ESMO Virtual Congress | |
dc.contributor.author | Giaccone, G. | |
dc.contributor.author | Felip, E. | |
dc.contributor.author | Cobo, M. | |
dc.contributor.author | Garcia Campelo, R. | |
dc.contributor.author | Denis, F. | |
dc.contributor.author | Quoix, E. | |
dc.contributor.author | Madroszyk, A. | |
dc.contributor.author | Debieuvre, D. | |
dc.contributor.author | Hilgers, W. | |
dc.contributor.author | Moran, T. | |
dc.contributor.author | Galetta, D. | |
dc.contributor.author | Romano, G. D. | |
dc.contributor.author | Cappuzzo, F. | |
dc.contributor.author | Robinet, G. | |
dc.contributor.author | Masson, P. | |
dc.contributor.author | Viteri, S. | |
dc.contributor.author | Peled, N. | |
dc.contributor.author | Costantini, D. | |
dc.contributor.author | Dziadziuszko, R. | |
dc.contributor.author | Besse, B. | |
dc.contributor.authoraffiliation | [Giaccone, G.] Weill Cornell Med, Clin Res, New York, NY USA | |
dc.contributor.authoraffiliation | [Felip, E.] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain | |
dc.contributor.authoraffiliation | [Cobo, M.] Hosp Univ Reg & Virgen de la Victoria IBIMA, Unidad Gest Clin Intercentros Oncol Med, Malaga, Spain | |
dc.contributor.authoraffiliation | [Garcia Campelo, R.] Univ Hosp A Coruna, Med Oncol, La Coruna, Spain | |
dc.contributor.authoraffiliation | [Denis, F.] Clin Victor Hugo Le Mans, Med Oncol, Le Mans, France | |
dc.contributor.authoraffiliation | [Quoix, E.] Hop Univ Strasbourg, Nouvel Hop Civil, Pneumol Dept, Strasbourg, France | |
dc.contributor.authoraffiliation | [Madroszyk, A.] Inst Paoli Calmettes, Med Oncol, Marseille, France | |
dc.contributor.authoraffiliation | [Debieuvre, D.] Hop Emile Muller GHRMSA, Pneumol Dept, Mulhouse, France | |
dc.contributor.authoraffiliation | [Hilgers, W.] Inst Ste Catherine, Med Oncol, Avignon, France | |
dc.contributor.authoraffiliation | [Moran, T.] Hosp Badalona Germans Trias & Pujol, ICO Badalona, B ARGO, Med Oncol, Barcelona, Spain | |
dc.contributor.authoraffiliation | [Galetta, D.] Ist Tumori Giovanni Paolo II, Med Thorac Oncol Dept, Bari, Italy | |
dc.contributor.authoraffiliation | [Romano, G. D.] Osped Vito Fazzi, Dept Oncol, Lecce, Italy | |
dc.contributor.authoraffiliation | [Cappuzzo, F.] AUSL Romagna, Department Oncol & Hematol, Ravenna, Italy | |
dc.contributor.authoraffiliation | [Robinet, G.] CHU Brest, Hop Morvan, Med Oncol, Brest, France | |
dc.contributor.authoraffiliation | [Masson, P.] Ctr Hosp Cholet, Pneumol Dept, Cholet, France | |
dc.contributor.authoraffiliation | [Viteri, S.] Hosp Univ Dexeus, Inst Oncol Dr Rosell, Grp QuironSalud, Dept Oncol, Barcelona, Spain | |
dc.contributor.authoraffiliation | [Peled, N.] Soroka Univ Med Ctr, Canc Ctr, Beer Sheva, Israel | |
dc.contributor.authoraffiliation | [Costantini, D.] OSE Immunotherapeut, Dev, Paris, France | |
dc.contributor.authoraffiliation | [Dziadziuszko, R.] Med Univ Gdansk, Oncol & Radiotherapy, Gdansk, Poland | |
dc.contributor.authoraffiliation | [Besse, B.] Gustave Roussy, Med Oncol, Villejuif, France | |
dc.contributor.funder | OSE Immunotherapeutics | |
dc.date.accessioned | 2025-01-07T15:15:37Z | |
dc.date.available | 2025-01-07T15:15:37Z | |
dc.date.issued | 2020-09-01 | |
dc.identifier.doi | 10.1016/j.annonc.2020.08.1574 | |
dc.identifier.essn | 1569-8041 | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.unpaywallURL | http://www.annalsofoncology.org/article/S0923753420415704/pdf | |
dc.identifier.uri | https://hdl.handle.net/10668/26992 | |
dc.identifier.wosID | 573469101546 | |
dc.issue.number | 4 | |
dc.journal.title | Annals of oncology | |
dc.journal.titleabbreviation | Ann. oncol. | |
dc.language.iso | en | |
dc.organization | SAS - Hospital Universitario Virgen de la Victoria | |
dc.organization | SAS - Hospital Universitario Regional de Málaga | |
dc.organization | Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA) | |
dc.page.number | S814-S815 | |
dc.publisher | Elsevier | |
dc.rights.accessRights | open access | |
dc.title | Activity of OSE-2101 in HLA-A2+non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial | |
dc.type | conference output | |
dc.type.hasVersion | VoR | |
dc.volume.number | 31 | |
dc.wostype | Meeting Abstract |